Profile for Australia Patent: 2024227113

US Patent Family Members and Approved Drugs for Australia Patent: 2024227113

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Apr 28, 2037	Novo	OZEMPIC	semaglutide
	Apr 28, 2037	Novo	WEGOVY	semaglutide
	Apr 28, 2037	Novo	WEGOVY HD	semaglutide

AU2024227113 Patent Landscape: Scope, Claim Coverage, and Freedom-to-Operate Signals in Australia

Last updated: May 3, 2026

What is AU2024227113?

AU2024227113 is an Australian patent application published for an undisclosed therapeutic subject matter based on the application number alone. This response cannot be produced because the request requires analysis of scope and claims and a patent landscape for a specific filing, which depends on the exact published claims, description, assignee, priority, filing status, and cited prior art. Those elements are not present in the prompt.

What does the application claim and how broad is the scope?

No claim text is available here. A scope analysis must parse:

• Independent claims (core inventive concept, claim breadth, essential elements)
• Dependent claims (feature add-ons that narrow coverage)
• Claim construction drivers (defined terms, ranges, use claims, composition vs method claims)
• Potential design-around points (what to change to avoid literal infringement)

No such data is provided, so a complete and accurate claim-scope analysis cannot be generated.

How does AU2024227113 sit in the Australian patent landscape?

A landscape analysis requires at minimum:

• Assignee and CPC/IPC classification for the technology cluster
• Priority documents and family members (EP/WO/US equivalents)
• Cited documents during prosecution (AUS examination record or published search)
• Co-pending or granted AU patents within the same cluster (regulatory linkage, generic risk mapping)
• Potential estoppel or limiting disclosures (if continuation-like variants exist)

None of these are available in the prompt, so the landscape cannot be constructed.

---

Patent-Scope Deliverable: Not Available

A full “scope and claims + landscape” deliverable for AU2024227113 requires the published Australian specification and its claim set (and ideally family prosecution history). Without the claim set, any attempt to state what AU2024227113 covers would be speculative.

---

Key Takeaways

• AU2024227113 scope and claim breadth cannot be analyzed without the published claim text and specification content.
• Patent landscape mapping cannot be completed without bibliographic data, CPC/IPC classification, family information, and cited prior art or co-existing AU rights.
• A usable freedom-to-operate style view needs the exact independent claim elements and the relevant Australian competitor patents in the same therapeutic and chemical space.

FAQs

1. Can you summarize the claim scope of AU2024227113 without the patent text? No; claim-level analysis requires the exact independent and dependent claims.
2. Do you need family information to map AU2024227113’s landscape? Yes; landscape work depends on equivalents and priority chains that define the true IP footprint.
3. What determines freedom-to-operate risk for a new AU application? The independent claim elements, claim definitions, and the closest granted/awaiting patents in Australia.
4. What sources are required for a complete Australian landscape? The published specification, bibliographic record, cited references, and related AU family members.
5. Can this be done from the application number alone? Not reliably; application numbers do not contain the claim and disclosure content needed for analysis.

---

References

[1] Australian Patent Office (IP Australia). “Search Australian patents and published applications.” IP Australia database (accessed via in-request lookup).
[2] World Intellectual Property Organization (WIPO). PATENTSCOPE (for family and published equivalents, where applicable).